Themis Bioscience’s Vaccine Against Chikungunya Successful in Phase 1

News   Nov 21, 2014

 
Themis Bioscience’s Vaccine Against Chikungunya Successful in Phase 1
 
 
 

RELATED ARTICLES

Cobra Biologics Awarded £2.6m ($3.4m USD) from Innovate UK

News

Capital infrastructure investment to embed and secure clinical and commercial viral vector manufacturing capability within the UK. Award made as part of UK’s Innovation Agency’s Industrial Strategy boost for UK medicines with £70m of funding to help develop new treatments.

READ MORE

Scientists with Novel Approaches to Fighting Cancer Awarded $3M

News

The Damon Runyon Cancer Research Foundation announced that ten scientists with novel approaches to fighting cancer have been named 2018 recipients of the Damon Runyon-Rachleff Innovation Award.

READ MORE

Anti-Inflammatory Pill Could Make Vaccines More Effective for the Elderly

News

By identifying why skin immunity declines in old age, a UCL-led research team has found that an anti-inflammatory pill could help make vaccines more effective for elderly people.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE